Outcomes of Radium-223 and Stereotactic Ablative Radiotherapy Versus Stereotactic Ablative Radiotherapy for Oligometastatic Prostate Cancers: The RAVENS Phase II Randomized Trial

Overview of attention for article published in Journal of Clinical Oncology, May 2025

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (97th percentile)
High Attention Score compared to outputs of the same age and source (93rd percentile)

Mentioned by

news: 4 news outlets
blogs: 2 blogs
twitter: 31 X users

guideline: 1 clinical guideline source
bluesky: 1 Bluesky user

Readers on

mendeley: 23 Mendeley

So far, Altmetric has seen 2 posts from 2 blogs.

HMN 2025: How Radiopharmaceutical added to stereotactic radiation can delay prostate cancer progression

Health Medicine Network, 29 Sep 2025

A new clinical trial finds that people with a limited number of metastases from recurrent prostate cancer lived significantly…

Outcomes of Radium-223 and Stereotactic Ablative Radiotherapy Versus Stereotactic Ablative Radiotherapy for Oligometastatic Prostate Cancers: The RAVENS Phase II Randomized Trial

Stemcell science news, 09 May 2025

Scientists hypothesized the BM-targeting alpha-emitter radium-223 dichloride (Ra223) could target subclinical bone disease and…

This page shows the most recent blog posts that mention this research output. Click here to find out how to access more activity.